#NIAID

This NIH study closely monitored 10 people with HIV who stopped antiretroviral treatment for weeks to months in a larger cure study.

A trial of long-acting cabotegravir injected every eight weeks is already under way among men who have sex with men and trans women.

Although we have the tools to end the epidemic through treatment and PrEP, costs and other considerations limit these methods.

Here’s how you can take action to support rectal microbicide research.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.

HIV prevention efforts would also take a huge hit under Trump’s draconian proposed budget cuts and the House health care bill.

With a major new HIV vaccine trial under way, cautious optimism is stirring that the vaccine will prove effective enough for a rollout.

The goal is to manufacture HIV envelope protein immunogens that prevent HIV infection.

How long did it take to develop other vaccines? Check out this AVAC chart.

Recipients Anthony Fauci oversees “critical” research in the United States and Frank Plummer did “groundbreaking” work in Africa.

NIAID research will build on the ASPIRE trials. Those findings showed that dapivirine rings provided “modest” HIV protection.

For the first time, a major clinical trial has found that starting antiretroviral treatment soon after HIV diagnosis reduces the risk of sickn...

Monday, May 18, is HIV Vaccine Awareness Day (HVA), a time to educate about the importance of a vaccine and to thank those working to find an...

Two Duke research teams received multiyear grants from NIAID totaling $20 million for work on HIV vaccines.

New research has shown that broadly neutralizing antibodies can block HIV from entering into or replicating inside of CD4 cells in a laborator...